when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

LILLY · news · pharmadog

← back to LILLY

News mentioning LILLY

309 stories

May 18, 26STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much morestat

May 15, 26STAT+: Takeda will pay $13.6 million to settle allegations it paid kickbacks to doctorsstat

May 15, 26STAT+: Up and down the ladder: The latest comings and goingsstat

May 15, 26STAT+: Pharmalittle: We’re reading about U.S. pressuring Germany on drug prices, FDA upheaval and biotech clinical trials, and morestat

May 14, 26Makary’s departure and Cassidy’s tenuous Senate seatstat

May 14, 26Create Medicines raises $122M to bolster in vivo CAR-T therapiesbiopharma dive

May 14, 26STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much morestat

May 13, 26U.S. overdose deaths fell again in 2025, but some worry about policy and drug supply changesstat

May 13, 26Lilly data point to ‘maintenance’ strategies for GLP-1 weight lossbiopharma dive

May 13, 26The ‘velocity of obesity’ aims to show which nations are slowing an epidemicstat

May 13, 26Assertio accepts new buyout bid; AI biotech Isomorphic banks $2Bbiopharma dive

May 13, 26STAT+: Pharmalittle: We’re reading about FDA’s Makary resigning, a Lilly weight loss drug trial, and morestat

May 12, 26Lilly points to low-dose Zepbound and Foundayo as weight loss maintenance optionsendpoints

May 12, 26Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drugbiopharma dive

May 12, 26STAT+: Pharmalittle: We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and morestat

May 12, 26A year after Vertex’s big launch, pain drug research faces a pivotal momentbiopharma dive

May 11, 26STAT+: Medicare is spending far less than expected on new Alzheimer’s drugsstat

May 8, 26Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Canceronclive

May 8, 26Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Canceronclive

May 8, 26Lilly to invest extra $4.5B across Indiana manufacturingbiopharma dive

May 8, 26Lilly, Gilead lead pharma’s M&A boombiopharma dive

May 8, 26STAT+: Pharmalittle: We’re reading about an FDA gender rule change, its program for one-day inspections, and morestat

May 7, 26Seaport’s IPO adventure, obesity pill battles, and Makary’s troublesstat

May 7, 26Angelini to buy Catalyst in $4B play for rare neuro drugsbiopharma dive

May 7, 26STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and morestat

May 7, 26STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1Bstat

May 6, 26STAT+: Oregon hospitals won’t outsource to national physician chain after allstat

May 6, 26Lilly plans new $4.5B manufacturing investment in Indianaendpoints

May 6, 26Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Canceronclive

May 6, 26STAT+: Color Health moving deeper into cancer services, complete with virtual ‘tumor boards’stat

← prevpage 9 of 11next →